Flag of the European Union EU Clinical Trials Register Help

Clinical trials for acne

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    181 result(s) found for: acne. Displaying page 6 of 10.
    «« First « Previous 2  3  4  5  6  7  8  9  10  Next»
    EudraCT Number: 2023-000462-33 Sponsor Protocol Number: 171-7151-202 Start Date*: 2023-04-19
    Sponsor Name:Intrepid Therapeutics, Inc.
    Full Title: An Open Label Evaluation of the Adrenal Suppression Potential and Pharmacokinetic Properties of Cortexolone 17α-Propionate (CB-03-01) Cream Applied Every 12 Hours for Two Weeks in Subjects with Acn...
    Medical condition: Facial Acne Vulgaris
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2005-004640-31 Sponsor Protocol Number: TUD-Akne02-003 Start Date*: 2006-02-15
    Sponsor Name:Technische Universität Dresden
    Full Title: Control of therapy of acne papulopustulosa by visible light with waterfiltered infrared and / or Adapalen (Differin Gel)
    Medical condition: Acne papulopustulos
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: View results
    EudraCT Number: 2020-002607-19 Sponsor Protocol Number: 77474462HDS2001 Start Date*: 2021-10-07
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 2a/2b, Multicenter, Randomized, Placebo and Active Comparator-controlled, Double-Blind, Dose-ranging Study to Evaluate the Safety and Efficacy of Bermekimab (JNJ-77474462) for the Treatment...
    Medical condition: Moderate to Severe Hidradenitis Suppurativa
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10020041 Hidradenitis suppurativa LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Prematurely Ended) ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2020-003672-40 Sponsor Protocol Number: 1368-0052 Start Date*: 2021-03-02
    Sponsor Name:Boehringer Ingelheim France
    Full Title: Randomized, double-blind, placebo-controlled, study of spesolimab in patients with moderate or severe hidradenitis suppurativa
    Medical condition: hidradenitis suppurativa
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10020041 Hidradenitis suppurativa LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) HU (Completed) CZ (Completed) BE (Completed) NL (Completed) DE (Completed) GR (Prematurely Ended) IT (Completed) ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2020-005587-55 Sponsor Protocol Number: 1368-0067 Start Date*: 2021-06-03
    Sponsor Name:Boehringer Ingelheim France
    Full Title: An open-label, long-term extension trial of spesolimab treatment in adult patients with Hidradenitis Suppurativa (HS)
    Medical condition: Hidradenitis Suppurativa
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10020041 Hidradenitis suppurativa LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) HU (Prematurely Ended) DE (Completed) NO (Completed) CZ (Completed) NL (Completed) BE (Prematurely Ended) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2017-002612-14 Sponsor Protocol Number: TMP-0517 Start Date*: 2019-06-25
    Sponsor Name:Fraunhofer Gesellschaft for its Institute Fraunhofer Institute for Molecular Biology and Applied Ecology (IME)
    Full Title: Preliminary efficacy and safety of Apremilast in the treatment of acne conglobata: A phase II, single centre, open label, proof of concept study for the treatment of acne conglobata with the PDE-4 ...
    Medical condition: Mild to severe Acne conglobata in adults (ages 18 to 65 years, inclusive)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10000501 Acne conglobata PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-004587-38 Sponsor Protocol Number: M10-467 Start Date*: 2009-06-03
    Sponsor Name:Abbott GmbH & Co. KG
    Full Title: A Phase 2 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects with Moderate to Severe Chronic Hidradenitis Suppurativa
    Medical condition: Hidradenitis Suppurativa (HS) is a painful, chronic, skin disease characterized by recurrent inflamed nodules, abscesses, and fistulas, which may heal with scarring. The most commonly involved ana...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020041 Hidradenitis suppurativa LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2011-003400-20 Sponsor Protocol Number: M11-313 Start Date*: 2012-04-12
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects with Moderate to Severe Hidradenitis Suppurativa
    Medical condition: Hidradenitis Suppurativa
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004858 10020041 Hidradenitis suppurativa LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2021-005928-38 Sponsor Protocol Number: M1095-HS-201 Start Date*: 2022-08-23
    Sponsor Name:MoonLake Immunotherapeutics AG
    Full Title: Phase 2, randomized, parallel-group, double-blind, placebo-controlled study of sonelokimab in patients with active moderate to severe hidradenitis suppurativa
    Medical condition: Active moderate to severe hidradenitis suppurativa
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10020041 Hidradenitis suppurativa LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) NL (Completed) BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-002063-26 Sponsor Protocol Number: CAIN457M2301 Start Date*: 2019-01-16
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, double-blind, multicenter study assessing short (16 weeks) and long-term efficacy (up to 1 year), safety, and tolerability of 2 subcutaneous secukinumab dose regimens in adult patient...
    Medical condition: hidradenitis suppurativa
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10020041 Hidradenitis suppurativa LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) DE (Completed) PT (Completed) HU (Completed) SK (Completed) CZ (Completed) BE (Completed) GR (Completed) AT (Completed) SE (Completed) ES (Completed) BG (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-004108-33 Sponsor Protocol Number: M20-262 Start Date*: 2022-03-09
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Phase 2 Multicenter, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lutikizumab (ABT-981) in Adult Subjects with Moderate to Severe Hidradenitis Suppurat...
    Medical condition: Hidradenitis Suppurativa
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10020041 Hidradenitis suppurativa LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-005713-13 Sponsor Protocol Number: 21102 Start Date*: 2022-08-16
    Sponsor Name:ACELYRIN, INC.
    Full Title: A Phase 2b Pivotal Study to Evaluate the Efficacy and Safety of Izokibep in Subjects with Moderate to Severe Hidradenitis Suppurativa
    Medical condition: Hidradenitis Suppurativa
    Disease: Version SOC Term Classification Code Term Level
    27.1 10040785 - Skin and subcutaneous tissue disorders 10020041 Hidradenitis suppurativa LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Ongoing) HU (Completed)
    Trial results: View results
    EudraCT Number: 2019-002550-23 Sponsor Protocol Number: HS0003 Start Date*: 2020-04-24
    Sponsor Name:UCB Biopharma SRL
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa
    Medical condition: Hidradenitis Suppurativa
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10020041 Hidradenitis suppurativa LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GR (Completed) BE (Completed) NL (Completed) DK (Completed) ES (Ongoing) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-002757-30 Sponsor Protocol Number: CCFZ533H12201BC Start Date*: 2019-03-28
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, subject and investigator blinded, placebo controlled and multi-center platform study, to assess efficacy and safety of different investigational drugs in patients with moderate to sev...
    Medical condition: Hidradenitis suppurativa
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10020041 Hidradenitis suppurativa LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) HU (Trial now transitioned) DK (Completed) NL (Completed) IS (Completed) CZ (Completed) BE (Trial now transitioned) ES (Restarted)
    Trial results: (No results available)
    EudraCT Number: 2015-005161-23 Sponsor Protocol Number: M15-574 Start Date*: 2016-08-30
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Phase 4, Double-Blind, Randomized, Placebo-Controlled Multicenter Study to Assess the Safety and Efficacy of Adalimumab Used in Conjunction with Surgery in Subjects with Moderate to Severe Hidrad...
    Medical condition: Hidradenitis Suppurativa (also known as Acne inversa)
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004858 10020041 Hidradenitis suppurativa LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) SE (Completed) NL (Completed) GB (Completed) DE (Completed) IE (Completed) PT (Completed) GR (Completed) BE (Completed) ES (Completed) CZ (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-002062-39 Sponsor Protocol Number: CAIN457M2302 Start Date*: 2019-01-17
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, double-blind, multicenter study assessing short (16 weeks) and long-term efficacy (up to 1 year), safety, and tolerability of 2 subcutaneous secukinumab dose regimens in adult patient...
    Medical condition: hidradenitis suppurativa
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10020041 Hidradenitis suppurativa LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) DE (Completed) SK (Completed) CZ (Completed) BE (Completed) DK (Completed) LT (Completed) GR (Completed) NL (Completed) ES (Completed) HU (Completed) PL (Completed) BG (Completed) HR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-003230-17 Sponsor Protocol Number: CAIN457M2301E1 Start Date*: 2020-01-22
    Sponsor Name:Novartis Pharma AG
    Full Title: A Multicenter, Double-blind, Randomized Withdrawal extension study of subcutaneous secukinumab to demonstrate long-term efficacy, safety and tolerability in subjects with moderate to severe hidrade...
    Medical condition: hidradenitis suppurativa
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10020041 Hidradenitis suppurativa LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) GR (Trial now transitioned) ES (Ongoing) FR (Completed) PT (Trial now transitioned) CZ (Trial now transitioned) SK (Trial now transitioned) LT (Trial now transitioned) AT (Trial now transitioned) NL (Trial now transitioned) DK (Prematurely Ended) IT (Trial now transitioned) HR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2023-000461-13 Sponsor Protocol Number: 171-7151-201 Start Date*: 2023-04-19
    Sponsor Name:Intrepid Therapeutics Inc.
    Full Title: A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Dose Escalating Study to Evaluate the Safety and Efficacy of Cortexolone 17α-Propionate (CB-03-01) Cream Applied Once or Twice-...
    Medical condition: Facial Acne Vulgaris
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2006-000390-30 Sponsor Protocol Number: ML20128 Start Date*: 2006-05-18
    Sponsor Name:Helsinki University Central Hospital, Skin and Allergy Hospital
    Full Title: A phase II trial assessing dapsone topical gel in the prevention and treatment of erlotinib associated rash
    Medical condition: The study population are patients with non-small cell lung carcinoma eligible for treatment with erlotinib (TarcevaTM). A significant number of these patients develop acne-like rash as a side effec...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-000892-10 Sponsor Protocol Number: HS0001 Start Date*: 2017-11-22
    Sponsor Name:UCB Biopharma SPRL
    Full Title: A Phase 2 Multicenter, Investigator-blind, Subject-blind, Placebo-controlled Study of the Efficacy, Safety, and Pharmacokinetics of Bimekizumab in Subjects with Moderate to Severe Hidradenitis Supp...
    Medical condition: Hidradenitis Suppurativa
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10020041 Hidradenitis suppurativa LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) DK (Completed) GR (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 2  3  4  5  6  7  8  9  10  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Jun 02 21:17:13 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA